XTL Historical Income Statement
| XTLB Stock | USD 2.10 0.22 11.70% |
Historical analysis of XTL Biopharmaceutica income statement accounts such as Other Operating Expenses of 726.8 K, Research Development of 29.4 K, Total Operating Expenses of 726.8 K or Interest Expense of 565.1 K can show how well XTL Biopharmaceuticals Ltd performed in making a profits. Evaluating XTL Biopharmaceutica income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of XTL Biopharmaceutica's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining XTL Biopharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XTL Biopharmaceuticals is a good buy for the upcoming year.
XTL |
About XTL Income Statement Analysis
XTL Biopharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to XTL Biopharmaceutica shareholders. The income statement also shows XTL investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
XTL Biopharmaceutica Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of XTL Biopharmaceuticals. It is also known as XTL Biopharmaceutica overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from XTL Biopharmaceutica's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into XTL Biopharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, XTL Biopharmaceutica's Interest Expense is projected to increase significantly based on the last few years of reporting. Total Revenue is expected to grow at the current pace this year, whereas Other Operating Expenses is forecasted to decline to about 726.8 K.
XTL Biopharmaceutica income statement Correlations
Click cells to compare fundamentals
XTL Biopharmaceutica Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XTL Biopharmaceutica income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Operating Expenses | 842K | 948K | 1.0M | 880K | 765K | 726.8K | |
| Operating Income | (842K) | (948K) | (1.0M) | (880K) | (765K) | (803.3K) | |
| Ebit | (439.9K) | (948K) | (1.0M) | (880K) | (765K) | (803.3K) | |
| Research Development | 43K | 38K | 35K | 30K | 31K | 29.5K | |
| Ebitda | (268K) | (947K) | (1.0M) | (879K) | (764K) | (802.2K) | |
| Total Operating Expenses | 842K | 948K | 1.0M | 880K | 765K | 726.8K | |
| Net Income | (1.3M) | (782K) | 435K | (1.3M) | (1.8K) | (1.9K) | |
| Income Tax Expense | (69K) | (166K) | (1.5M) | 468K | (167.9K) | (159.5K) | |
| Income Before Tax | (1.3M) | (782K) | 435K | (1.3M) | (1.8M) | (1.9M) | |
| Total Other Income Expense Net | (505K) | (2.0M) | 1.5M | (468K) | (1.0M) | (966.2K) | |
| Depreciation And Amortization | 52.5K | 161.1K | 171.9K | 1K | 900.0 | 855.0 | |
| Selling General Administrative | 807K | 910K | 1.0M | 850K | 734K | 697.3K | |
| Total Revenue | 52K | 69K | 28K | 1.5M | (459K) | 0.0 | |
| Gross Profit | 69K | 27K | 1.5M | (460K) | (414K) | (393.3K) | |
| Net Income Applicable To Common Shares | (1.3M) | (3.0M) | 435K | (1.3M) | (1.6M) | (1.6M) | |
| Net Income From Continuing Ops | (1.3M) | (782K) | 435K | (1.3M) | (2.2M) | (2.4M) | |
| Interest Income | 93K | 33K | 8K | 36K | 46K | 34.2K | |
| Net Interest Income | 64K | 16K | 3K | 25K | (28K) | (26.6K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.